BioNTech SE
SUBSTITUTED IMIDAZOQUINOLINES AS AGONISTS OF TLR7
Last updated:
Abstract:
The invention relates to imidazoquinoline derivatives and to pharmaceutical compositions containing the imidazoquinoline derivatives. The imidazoquinoline derivatives of the invention are useful as toll-like receptor agonists, in particular agonists of TLR7, and promote induction of certain cytokines. ##STR00001##
Status:
Application
Type:
Utility
Filling date:
10 Feb 2022
Issue date:
4 Aug 2022